Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suhasini Iyer

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Biopharmaceutics & Drug Disposition|April 24, 2015
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesAmrita V Kamath, Suhasini Iyer
Pharmaceutical Research|December 3, 2014
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesAmrita V Kamath, Suhasini Iyer
Current Pharmaceutical Design|October 9, 2002
Rational design and development of RDP58Suhasini Iyer, Roger Lahana, Roland Buelow
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2012
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Rong Deng, Feng Jin, Saileta Prabhu, et al.
Biopharmaceutics & Drug Disposition|April 15, 2015
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug developmentJing Wang, Suhasini Iyer, Paul J Fielder, et al.
Pharmaceutical Research|July 19, 2012
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in miceAnshu Marathe, Suhasini Iyer, Zhihua Julia Qiu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2013
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkeyChee M Ng, Kelly M Loyet, Suhasini Iyer, et al.
ACS Synthetic Biology|November 22, 2023
Evaluating DFHBI-Responsive RNA Light-Up Aptamers as Fluorescent Reporters for Gene ExpressionAlicia Climent-Catala, Ivan Casas-Rodrigo, Suhasini Iyer, et al.
Mabs|October 22, 2010
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?Rong Deng, Suhasini Iyer, Frank-Peter Theil, et al.
The Journal of Investigative Dermatology|August 25, 2005
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis modelChristopher G De Vry, Marybeth Valdez, Mirella Lazarov, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Biopharmaceutics & Drug Disposition|April 24, 2015
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesAmrita V Kamath, Suhasini Iyer
Pharmaceutical Research|December 3, 2014
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesAmrita V Kamath, Suhasini Iyer
Current Pharmaceutical Design|October 9, 2002
Rational design and development of RDP58Suhasini Iyer, Roger Lahana, Roland Buelow
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2012
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Rong Deng, Feng Jin, Saileta Prabhu, et al.
Biopharmaceutics & Drug Disposition|April 15, 2015
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug developmentJing Wang, Suhasini Iyer, Paul J Fielder, et al.
Pharmaceutical Research|July 19, 2012
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in miceAnshu Marathe, Suhasini Iyer, Zhihua Julia Qiu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 4, 2013
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkeyChee M Ng, Kelly M Loyet, Suhasini Iyer, et al.
ACS Synthetic Biology|November 22, 2023
Evaluating DFHBI-Responsive RNA Light-Up Aptamers as Fluorescent Reporters for Gene ExpressionAlicia Climent-Catala, Ivan Casas-Rodrigo, Suhasini Iyer, et al.
Mabs|October 22, 2010
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?Rong Deng, Suhasini Iyer, Frank-Peter Theil, et al.
The Journal of Investigative Dermatology|August 25, 2005
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis modelChristopher G De Vry, Marybeth Valdez, Mirella Lazarov, et al.
Pageof 4